Inactive Instrument

Lescarden Inc.

Equities

LCAR

US5268671063

Biotechnology & Medical Research

Lescarden Inc. Announces Resignation of George E. Ehrlich as Director

August 16, 2013 at 01:23 pm

Lescarden Inc. announced that Effective August 7, 2013, Dr. George E. Ehrlich resigned as a director of the company. Mr. Ehrlich's resignation from the Boards of Directors of the companies did not result from any disagreement with the company.

Latest news about Lescarden Inc.

Lescarden Inc. Auditor Raises 'Going Concern' Doubt	16-09-29	CI
Lescarden Inc. Auditor Raises 'Going Concern' Doubt	15-08-30	CI
Lescarden Inc. Auditor Raises 'Going Concern' Doubt	14-08-28	CI
Lescarden Inc. Reports Earnings Results for the Full Year Ended May 31, 2013	13-09-16	CI
Lescarden Inc. Auditor Raises 'Going Concern' Doubt	13-08-29	CI
Lescarden Inc. Announces Resignation of George E. Ehrlich as Director	13-08-16	CI
Lescarden Inc. announced that it has received $0.20 million in funding.	12-09-24	CI
Lescarden Inc. Auditor Raises 'Going Concern' Doubt	12-08-29	CI
Lescarden Inc. announced a financing transaction.	12-08-08	CI

Chart Lescarden Inc.

Duration

Period

More charts

Company Profile

Lescarden Inc. is engaged in the research, testing and development of medications for the control and cure of various diseases, and the licensing of its technologies for commercialization by other companies. The Company's product line is led by Catrix Wound Dressing, a powder derived from bovine cartilage for the management of chronic lesions and burns, and helpful when applied to non-healing wounds, such as decubitus ulcers, venous stasis ulcers and diabetic ulcers. It also offers Catrix-based skin care products targeting the plastic surgery, dermatology and medical spa markets. It sells two nutritional supplements, including Bio-Cartilage and Poly-NAG, a glucosamine polymer. It has also developed a 5% Catrix Rejuvenation Cream and a 5% Catrix Lip Balm. Derived from specially processed crustacean shells, Poly-NAG is a polymeric form of glucosamine (Poly-N-Acetyl-D-Glucosamine) that is marketed by the Company in the anti-arthritic market as a treatment for osteoarthritis.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+51.85%	57.87B
LONZA GROUP AG	+41.42%	40.25B
IQVIA HOLDINGS INC.	-5.25%	39.94B
CELLTRION, INC.	-5.16%	28.54B
ICON PUBLIC LIMITED COMPANY	+12.79%	26.4B
ALNYLAM PHARMACEUTICALS, INC.	-20.18%	19.33B
MEDPACE HOLDINGS, INC.	+30.88%	12.4B
BIO-TECHNE CORPORATION	+0.61%	12.23B
UNITED THERAPEUTICS CORPORATION	+25.06%	12.2B

Other Biotechnology & Medical Research